NCT07517640 2026-04-08
Combining Furmonertinib With Local Therapy for Inoperable Early-stage Lung Cancer: A Phase II Trial
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Not yet recruiting
Clinical Trials
5 trialsNCT06812871 2026-04-02
High-dose Furmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Meningeal Metastasis
Sun Yat-sen University
Phase 2 Completed
NCT07348965 2026-04-02
Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis
Guangzhou University of Traditional Chinese Medicine
Phase NA Recruiting
NCT07482605 2026-03-20
Furmonertinib Plus Radiotherapy for EGFR+ NSCLC With Pleural Effusion
Jiangmen Central Hospital
Phase 2 Not yet recruiting
NCT07365410 2026-01-26
Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting